Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | ST6GAL1 | P15907 | 5/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.32 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2816616 | 1.00 | TYMP (0.41) | TYMPTHRBST6GAL1LMNAMTOR | |
| SCHEMBL2816907 | 0.88 | TYMP (0.40) | TYMPTHRBNT5ESLC6A1SLC6A11 | |
| SCHEMBL13134715 | 0.86 | TYMP (0.40) | TYMPTHRBNT5ESLC6A1SLC6A11 | |
| SCHEMBL1739171 | 0.86 | TYMP (0.47) | TYMPTHRBST6GAL1LMNAMTOR | |
| SCHEMBL20527120 | 0.86 | TYMP (0.41) | TYMPTHRBST6GAL1LMNAMTOR | |
| SCHEMBL25845635 | 0.83 | LMNA (0.41) | THRBST6GAL1LMNAMTORMDM2 | |
| SCHEMBL22577469 | 0.82 | TYMP (0.40) | TYMPTHRBSLC6A1SLC6A11 | |
| SCHEMBL17223094 | 0.82 | TYMP (0.51) | TYMPTHRBST6GAL1LMNAMTOR | |
| SCHEMBL2814330 | 0.82 | ST6GAL1 (0.35) | TYMPTHRBST6GAL1LMNAMTOR | |
| SCHEMBL1738534 | 0.81 | LMNA (0.41) | THRBST6GAL1LMNAMTORMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2623104-A1 | Substituted nucleoside and nucleotide analogs | Alios Biopharma, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | PNP, TYMP, NTPCR | TYMP 2/4885THRB 3293/4885ST6GAL1 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.